Although targeted therapies for FLT3 mutant AML are available with several agents approved by the FDA, the access to these agents globally and even within nonurban domestic regions is uncertain, therefore these behavioral modifications may have broad impact in underserved populations. Here, FLT3 is linked to acute myeloid leukemia.